| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022104644 |
| P356 | DOI | 10.1186/1471-2288-12-152 |
| P932 | PMC publication ID | 3570315 |
| P698 | PubMed publication ID | 23043545 |
| P5875 | ResearchGate publication ID | 232221797 |
| P50 | author | Jeroen P Jansen | Q95974394 |
| P2093 | author name string | Shannon Cope | |
| P2860 | cites work | Evaluating novel agent effects in multiple-treatments meta-regression | Q50674589 |
| Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. | Q51050316 | ||
| Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation | Q51835764 | ||
| Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors | Q51990048 | ||
| Bayesian measures of model complexity and fit | Q56532420 | ||
| Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis | Q57995927 | ||
| Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen | Q68217218 | ||
| Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma | Q72348198 | ||
| Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma | Q73181804 | ||
| Network meta-analysis for indirect treatment comparisons | Q74720205 | ||
| Network meta-analysis of parametric survival curves | Q85348089 | ||
| Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study | Q28250432 | ||
| Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma | Q28378420 | ||
| Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 | ||
| Network meta-analysis of individual and aggregate level data | Q30969336 | ||
| Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. | Q33337168 | ||
| Network meta-analysis of survival data with fractional polynomials | Q33891529 | ||
| Simultaneous comparison of multiple treatments: combining direct and indirect evidence. | Q34081552 | ||
| Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves | Q34148380 | ||
| Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide | Q34557762 | ||
| Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr | Q34747181 | ||
| Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment | Q36991744 | ||
| A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered | Q37373846 | ||
| Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. | Q37888895 | ||
| Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies | Q38523764 | ||
| Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma | Q43874888 | ||
| Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma | Q44191317 | ||
| Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial | Q44735204 | ||
| Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons | Q44749793 | ||
| Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1 | Q46894544 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | meta-analysis | Q815382 |
| heterogeneity | Q928498 | ||
| meta-regression | Q6822263 | ||
| P304 | page(s) | 152 | |
| P577 | publication date | 2012-10-08 | |
| P1433 | published in | BMC Medical Research Methodology | Q15752152 |
| P1476 | title | Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes | |
| P478 | volume | 12 |
| Q30967736 | A multivariate model for the meta-analysis of study level survival data at multiple times |
| Q33830562 | A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer |
| Q93136489 | An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma |
| Q38520487 | Assessing key assumptions of network meta-analysis: a review of methods |
| Q58116045 | Assessing the consistency assumptions underlying network meta-regression using aggregate data |
| Q36100127 | Assumptions of Mixed Treatment Comparisons in Health Technology Assessments - Challenges and Possible Steps for Practical Application |
| Q38662083 | Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models. |
| Q93161498 | Comparison of ventilatory modes to facilitate liberation from mechanical ventilation: protocol for a systematic review and network meta-analysis |
| Q96162477 | Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves |
| Q36046918 | Efficacy of limited fluid resuscitation in patients with hemorrhagic shock: a meta-analysis |
| Q49996939 | Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials |
| Q30694964 | Existing trial data do not support that hydroxyethyl starch is less harmful when given on more 'correct' indications |
| Q38436829 | Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network meta-analysis. |
| Q30251972 | GetReal in network meta-analysis: a review of the methodology |
| Q93059837 | Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia |
| Q47161643 | Multiple Score Comparison: a network meta-analysis approach to comparison and external validation of prognostic scores |
| Q53747880 | Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma |
| Q38418984 | Network Meta-analysis: Users' Guide for Surgeons: Part I - Credibility |
| Q38418988 | Network Meta-analysis: Users' Guide for Surgeons: Part II - Certainty |
| Q38667868 | Network meta-analysis including treatment by covariate interactions: Consistency can vary across covariate values |
| Q35602850 | Network meta-analysis of longitudinal data using fractional polynomials |
| Q35034895 | Poor prognosis of phosphatase of regenerating liver 3 expression in gastric cancer: a meta-analysis |
| Q35056525 | Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making |
| Q28651174 | Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data |
| Q35914125 | Treatment of idiopathic pulmonary fibrosis: a network meta-analysis |
| Q89172310 | Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions? |
Search more.